Peer-reviewed veterinary case report
What splenic fibrohistiocytic nodules mean for dogs after spleen
By Moore, A S et al.·Published in Journal of veterinary internal medicine·2012·Veterinary Oncology Consultants, Australia·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Histologic and immunohistochemical review of splenic fibrohistiocytic nodules in dogs.
- Species:
- dog
Plain-English summary
A group of 32 dogs with splenic fibrohistiocytic nodules (SFHN) were treated by veterinary oncologists to understand their conditions better. The dogs were diagnosed with various diseases, including some that were benign and others that were aggressive, like histiocytic sarcoma, which had a poor survival rate of just 74 days. In contrast, some dogs with less aggressive conditions lived much longer, with a median survival of 883 days after surgery. This study suggests that distinguishing between these conditions can help veterinarians provide better prognoses for dogs with similar symptoms.
People also search for: dog splenic tumor prognosis · splenectomy survival in dogs · histiocytic sarcoma in dogs treatment
Abstract
BACKGROUND: Splenic fibrohistiocytic nodules (SFHN) are commonly diagnosed. It is suspected that these represent a heterogeneous group of malignant and nonmalignant diseases, separation of which could improve the ability of clinicians to prognosticate for dogs. HYPOTHESIS/OBJECTIVES: Immunohistochemistry will differentiate histologic diagnoses within the group of SFHN; survival after splenectomy is associated with those histologic types. ANIMALS: Thirty-two dogs with SFHN treated by or under direction from veterinary oncologists. METHODS: Retrospective case record analysis from dogs followed from splenectomy until death. Clinical, histopathologic, and immunohistochemistry data analyzed for an association with survival time. RESULTS: Thirty-two dogs had SFHN; grade 1 (2 dogs), grade 2 (9 dogs), and grade 3 (lymphoid percentage <40%; 21 dogs). Twenty-two dogs died, 10 were censored (9 alive median of 883 days after splenectomy). Median overall survival was 387 days, and grade 3 SFHN was negatively [corrected] associated with survival time as previously reported (P < .001). Of 31 available samples, dogs had diseases reclassified as nodular hyperplasia (13; 8 complex, 5 lymphoid including 2 marginal zone), lymphoma (4; 2 marginal zone lymphoma, 1 high grade B-cell lymphoma, and 1 marginal zone transitional to high grade B-cell lymphoma), 8 stromal sarcomas, and 6 histiocytic sarcomas. Dogs with histiocytic sarcoma had worse survival (median 74 days) than dogs with other diseases. CONCLUSIONS AND CLINICAL IMPORTANCE: Splenic histiocytic sarcoma is an aggressive disease; however, some dogs with stromal sarcomas had long survival times. The term SFHN is no longer warranted for this group of disorders.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/22882592/